Zeina Nahleh
Expertise in
7
conditions

Dr. Zeina Nahleh

Hematology Oncology
2950 Cleveland Clinic Boulevard, 
Weston, FL 
On Staff At
Offers Telehealth
35 Years of Experience
Referral may be required
Expertise in
7
conditions
2950 Cleveland Clinic Boulevard, 
Weston, FL 

Overview

Zeina Nahleh is a Hematologist Oncology provider practicing medicine in Weston, Florida. She has been practicing medicine for over 35 years.

Dr. Nahleh is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, Salpingo-Oophorectomy, and Advanced Bronchoscopy.

Dr. Nahleh is board certified in American Board Of Internal Medicine, 2003. She is actively involved in clinical research, co-authoring 91 peer reviewed articles and participating in 9 clinical trials.

Graduate Institution

American University Of Beirut, 1991.0

Residency

American University of Beirut

Specialties

Hematology Oncology

Licenses

Internal Medicine in OH

Board Certifications

American Board Of Internal Medicine, 2003

Fellowships

The George Washington University Medical Center

Hospital Affiliations

Cleveland Clinic Hospital

Languages Spoken

English
Arabic
French
Spanish

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AultCare
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
CommuniCare Advantage
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Primetime Health Plan
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE PART D
Provider Partners Health Plan
  • MEDICARE SNP
SummaCare
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Univera Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 23 Less Insurance Carriers -

Locations

Egil and Pauline Braathen Center/Maroone Cancer Center
2950 Cleveland Clinic Boulevard, Weston, FL 33331

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Enrollment Status: Completed
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: Apixaban
Study Phase: Phase 3
Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers
Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers
Enrollment Status: Completed
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drugs: Binimetinib, Palbociclib, Trifluridine+Tipiracil Hydrochloride
Study Phase: Phase 2
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

91 Total Publications

CLO26-097: Robotic-Assisted Bronchoscopy (RAB) Compared to CT-Guided Transthoracic Biopsy (CTTB) in the Diagnosis of Lung Malignancy.
CLO26-097: Robotic-Assisted Bronchoscopy (RAB) Compared to CT-Guided Transthoracic Biopsy (CTTB) in the Diagnosis of Lung Malignancy.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 01, 2026
Similar Doctors
Expertise in
32
conditions
Dr. Arun Nagarajan
Hematology Oncology
Expertise in
32
conditions
Dr. Arun Nagarajan
Hematology Oncology

Egil And Pauline Braathen Center/Maroone Cancer Center

2950 Cleveland Clinic Boulevard, 
Weston, FL 
 (0.1 miles away)
877-463-2010
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arun Nagarajan is a Hematologist Oncology provider practicing medicine in Weston, Florida. Dr. Nagarajan is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, Cholangiocarcinoma (Bile Duct Cancer), and Liver Embolization. Dr. Nagarajan is board certified in American Board Of Internal Medicine, 2004.

Expertise in
61
conditions
Dr. Chakra Chaulagain
Hematology Oncology
Expertise in
61
conditions
Dr. Chakra Chaulagain
Hematology Oncology

Egil And Pauline Braathen Center/Maroone Cancer Center

2950 Cleveland Clinic Boulevard, 
Weston, FL 
 (0.1 miles away)
877-463-2010
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Chakra Chaulagain is a Hematologist Oncology provider practicing medicine in Weston, Florida. Dr. Chaulagain is highly rated in 61 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Plasmacytoma, Tissue Biopsy, and Splenectomy. Dr. Chaulagain is board certified in American Board Of Internal Medicine, 2015.

Expertise in
37
conditions
Dr. Timmy Nguyen
Hematology Oncology
Expertise in
37
conditions
Dr. Timmy Nguyen
Hematology Oncology

Egil And Pauline Braathen Center/Maroone Cancer Center

2950 Cleveland Clinic Boulevard, 
Weston, FL 
 (0.1 miles away)
877-463-2010
Experience:
31+ years
Languages Spoken:
English, Vietnamese
See accepted insurances
Offers Telehealth

Timmy Nguyen is a Hematologist Oncology provider practicing medicine in Weston, Florida. He has been practicing medicine for over 31 years. Dr. Nguyen is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Colorectal Cancer, Gastroesophageal Junction Cancer, and Lynch Syndrome. Dr. Nguyen is board certified in American Board Of Internal Medicine, 2010.

Frequently Asked Questions about Dr. Zeina Nahleh

How do I make an appointment with Dr. Zeina Nahleh?

You can book an appointment with Dr. Zeina Nahleh by calling their office at 877-463-2010. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Zeina Nahleh a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Zeina Nahleh is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Zeina Nahleh specialize in?

While Dr. Zeina Nahleh is a Hematology Oncology, they have specific expertise in Breast Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Zeina Nahleh participate in research or clinical trials?

Yes. Dr. Zeina Nahleh has published 91 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Zeina Nahleh's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Zeina Nahleh accept my insurance?

Dr. Zeina Nahleh accepts most major insurance plans, including Aetna and Ambetter. We recommend calling the office directly at 877-463-2010 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nahleh's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile